Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells

Stem Cells Arabia

Status and phase: Unknown; Phase 1

Conditions: Use of Stem Cells for COVID-19 Treatment

Treatments: Biological: WJ-MSCs

Study type: Interventional

Funder types: Other

Identifiers

NCT04313322

COVID-19

Details and patient eligibility

About

The purpose of this study is to investigate the potential use of Wharton's Jelly Mesenchymal stem cells (WJ-MSCs) for treatment of patient diagnosed with Corona Virus SARS-CoV-2 infection, and showing symptoms of COVID-19.

Full description

COVID-19 is a condition caused by infection with Coronoa Virus (SARS-CoV-2). This virus has a high transmission rate and is spreading at very high rates. causing a worldwide pandemic. Patients diagnosed with COVID-19 and confirmed positive with the virus, will be given three IV doses of WJ-MSCs consisting of 1X10e6/kg. The three doses will be 3 days apart form each other.

Patients will be followed up for a period of three weeks to assess the severity of the condition and measure the viral titers.

Enrollment: 5 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

COVID-19 positive according to diagnosis and clinical management of COVID-19 criteria.

Exclusion criteria

• Participants in other clinical trials
• patients with malignant tumors
• pregnant and lactating women
• co-infection with other infectious viruses or bacteria
• History of several allergies
• Patients with history of pulmonary embolism
• any liver or kidney diseases
• HIV positive patients
• Considered by researchers to be not suitable to participate in this clinical trial
• Chronic heart failure with ejection fraction less than 30%.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

5 participants in 1 patient group

WJ-MSCs

Experimental group

Description:

WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs. WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously.

Treatment:

Biological: WJ-MSCs